|Day Low/High||66.01 / 67.83|
|52 Wk Low/High||11.57 / 116.75|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 7,551 contracts has been traded thus far today, a contract volume which is representative of approximately 755,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.5% of CLVS's average daily trading volume over the past month, of 1.8 million shares.
Clovis Oncology closed trading below $67 on Tuesday.
Here's a technical look at how to play a number of stocks trending higher with strong volume.
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in...
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.
AstraZeneca shares, meanwhile, were less-than-moved by the news.
Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.
In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $63.71, changing hands for $65.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.
The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.
Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc.
Animal health and oncology deal activity is heating up in 2017.
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 10,313 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.4% of CLVS's average daily trading volume over the past month of 1.4 million shares.
The number of new 12-month highs has climbed to 240.
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.
A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.
Clovis will market the new drug under the brand name Rubraca.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc.
Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.